ClinicalTrials.gg
Enrolling by invitationNCT06880796MBTUpdated Nov 16, 2026

Mindfulness-Based Therapy for Serious Mental Illness

An interventional study of Mindfulness-based therapy and Treatment as Usual (TAU) in Serious Mental Illness, Schizophrenia and Major Depressive Disorder, sponsored by Butler Hospital. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Butler Hospital · Not applicable, Interventional, and Treatment

Updated Nov 16, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,465 studies in Schizophrenia with a site in United States — 148 open to participants now, 166 under way, 22 of them phase 3. Schizophrenia · United States.

Planned enrollment
349th of 1,319
160 · median 66
Started
2025
with 41 others
No phase
479 of 1,465
71 open now
Primary completion
2029-04
later than 134 of 165 live
Registered
1,379th of 1,465
by date

Among the 1,465 studies in Schizophrenia with a site in United States, this one is the 349th largest by planned enrollment of the 1,319 interventional ones that give a count, is one of 42 that started in 2025, is one of 479 with no phase, reaches primary completion later than 134 of the 165 other live ones, and was the 1,379th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

148 of the 1,465 studies in Schizophrenia with a site in United States are open now. Recruiting first, the newest first:

143 more — sign in →

All 148 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,465 studies in Schizophrenia with a site in United States, or all of them as a file.
02

Study summary

Serious mental illness (SMI), encompassing schizophrenia-spectrum and major mood disorders, has been estimated to affect approximately 5.4% of the U.S. adult population each year. Research shows low rates of evidence-based treatment being provided to patients with SMI. This is unfortunate, because evidence-based psychological therapies have been shown to be effective for improving outcomes in SMI. One such efficacious psychological intervention is mindfulness-based therapy (MBT), which integrates mindfulness practice with cognitive-behavioral strategies to improve illness management. Previous trials conducted in the United Kingdom have shown that MBT improves symptoms and functioning in community-based outpatients with SMI, including in routine practice settings. In the U.S., most patients with SMI receive treatment at local community mental health centers (CMHCs). However, patients in CMHCs often cannot access evidence-based therapies like MBT due to the lack of trained staff able to provide these interventions. Further, previous studies of MBT have been conducted exclusively outside the U.S. It is essential to confirm that MBT is effective when delivered for patients with SMI in the U.S., and how it can be sustainably implemented in CMHCs where this clinical population is commonly treated. Thus, the investigators propose to test the effectiveness of MBT for SMI and study its implementation in a typical CMHC setting. The investigators will randomize 160 patients with SMI (psychotic-spectrum and major mood disorders) to receive treatment as usual (TAU) vs TAU plus MBT delivered by frontline clinicians in a large, diverse CMHC. The investigators will conduct blinded assessments at baseline and at 6- (mid), 12- (post), and 24-weeks (follow-up). Consistent with an experimental therapeutics approach, the investigators will examine potential mechanisms of action (e.g., mindfulness skills), as well as collect implementation-focused quantitative and qualitative data from our community partners (patients, administrators, clinicians). If found to be effective and aided by a certified training program and the implementation data collected, MBT could be adopted as a future evidence-based practice and integrated into the routine community care of patients with SMI, thereby reducing health disparities.

03

Conditions studied

  • Serious Mental Illness
  • Schizophrenia
  • Major Depressive Disorder
  • Bipolar Disorder
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Currently receiving treatment in a community mental health center
  • Diagnosed with schizophrenia-spectrum disorder or major mood disorder based on clinical interview
  • Age 18 years or older
  • Ability to speak and read English

Exclusion criteria

Exclusion Criteria:

  • Not clinically stable enough to participate in treatment.
  • Established weekly mindfulness practice
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
160 participants (estimated)

Study arms

  • Experimental
    Mindfulness-based therapy

    Mindfulness-based therapy is a type of psychotherapy that will be provided in a group format for 12 weeks.

    Behavioral: Mindfulness-based therapy

  • Active comparator
    Treatment as Usual

    Treatment as usually provided including pharmacotherapy, psychotherapy, and case management as indicated.

    Behavioral: Treatment as Usual (TAU)

Interventions

  • BehavioralMindfulness-based therapy

    Mindfulness-based therapy provided in a group format.

  • BehavioralTreatment as Usual (TAU)

    Treatment as usually provided.

06

What researchers measure

Primary outcomes

  1. Brief Psychiatric Rating Scale (BPRS)

    The interviewer-rated Brief Psychiatric Rating Scale is a measure of psychiatric symptom severity. The total score (sum of items) will be used to assess overall severity with scores ranging from 18 to 126 and higher scores indicating greater severity.

    Time frame: 24 weeks

Secondary outcomes

  1. WHO Quality of Life-BREF (WHOQOL-BREF)

    The WHOQOL-BREF is a 26-item self-report measure of quality of life. Items are rated on a scale from 1 to 5 with total scores ranging from 26 to 130, with higher scores indicating higher quality of life.

    Time frame: 24 weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — Deidentified data will be uploaded to the NIMH Data Archive.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Apr 2029, 40 months after the start.

Of 760 non-industry interventional studies with no phase under Schizophrenia, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 56. This study's planned 40 months is above that.

Counting every sponsor, half of 773 studies reached it within 32 months; a quarter within 16 and three quarters within 56.

Start moved once since we started tracking on Sep 25, 2026: Nov 2025 → Dec 2025, on Nov 16, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2025
First posted
Mar 18, 2025
StartActual
Dec 1, 2025was Nov 2025
Primary completionEst.
Apr 1, 2029
CompletionEst.
Dec 31, 2029
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Nov 25, 2025→Dec 1, 2025
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Start date Nov 25, 2025→Dec 1, 2025
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06880796
Lead sponsor
Butler Hospital
Responsible party
Sponsor
First posted
Mar 18, 2025
Start date
Dec 1, 2025
Primary completion
Apr 1, 2029 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Nov 16, 2026

Study contacts

Brandon Gaudiano, PhD
principal investigator · Butler Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion